Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial
نویسندگان
1 Barij Medicinal Plants Research Center, Kashan, Iran
2 Department of Anesthesiology, Faculty of Paramedical, Sabzevar University of Medical Sciences, Sabzevar, Iran
3 Non-Communicable Diseases Research Center, Department of Nutrition & Biochemistry, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
4 Department of Environmental Health, School of Health, Sabzevar University of Medical Sciences, Sabzevar, Iran
5 Department of Nursing, School of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar, Iran
6 Non-Communicable Diseases Research Center, Department of Nutrition & Biochemistry, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
doi
10.22038/ajp.2023.23447چکیده
Objective: This study assessed the effects of Aloe verasupplementation on serum inflammatory factors, blood sugar andlipid profiles in hemodialysis patients.Materials and Methods: Totally, 50 hemodialysis patients wereallocated randomly to either Aloe vera or placebo groups. TheAloe vera group received 2 Aloe vera capsules daily for 8 weeks(500 mg/day). Serum C-reactive protein (hs- CRP), Fasting bloodglucose (FBS), and lipid profiles levels were evaluated at thebaseline and the end of the eighth week.Results: Aloe vera supplementation for 8 weeks was associatedwith a significant reduction of serum hs- CRP (p=0.004), totalcholesterol (p=0.01), low density lipoprotein (LDL) (p=0.02) levesand increased high density lipoprotein (HDL) (p=0.002)concentration in the hemodialysis patients.Conclusion: Aloe vera supplementation is beneficial inimprovement of cardiovascular risk factors in hemodialysispatients
